Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $30 on shares of Nektar Therapeutics’ (NASDAQ: NKTR) stock. Mizuho analysts believe Nektar’s immuno-oncology candidate NKTR-214 is the company’s most valuable asset, as it could provide significant upside while the company’s royalty-generating portfolio maintains a more consistent revenue stream for the biotech company. Additionally, Nektar has formed collaborations with numerous pharmaceutical companies on its PEGylation platform, which also provides a predictable revenue stream and a stable foundation.
For more information, visit www.Nektar.com
About Nektar
Nektar Therapeutics is a research-based development stage biopharmaceutical company with a mission to discover and develop innovative medicines to address the unmet medical needs of patients. The company’s R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Leveraging its proprietary and proven chemistry platform, Nektar discovers and designs new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
